The HER-2/neu oncogene:: prognostic factor, predictive factor and target for therapy

被引：156

作者：

Ross, JS

Fletcher, JA

机构：

[1] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA

[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA USA

来源：

SEMINARS IN CANCER BIOLOGY | 1999年 / 9卷 / 02期

关键词：

breast neoplasms; proto-oncogene; HER-2; neu prognosis; therapy;

D O I：

10.1006/scbi.1998.0083

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor HER-2/neu has been widely studied in breast cancer. The potential value of HER-2/neu status for the prediction of disease outcome and response to therapy in breast cancer is presented in the light of a series of recently Published studies showing a range of impact on thp outcome of patients treated with hormonal, cytotoxic and radiation therapies, This review includes the application of serum-based HER-2/neu testing and the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment.

引用

页码：125 / 138

页数：14

共 136 条

[61]

LEAL CB, 1995, CANCER, V75, P2123, DOI 10.1002/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO

[62]

2-V

[63] ELEVATED SERUM C-ERBB-2 ANTIGEN LEVELS AND DECREASED RESPONSE TO HORMONE-THERAPY OF BREAST-CANCER [J].